Pulmonx Q2 FY26 net loss narrows 34% to $10.1 million; revenue drops 5% to $22.8 million - LUNG News | RalliesPulmonx Q2 FY26 net loss narrows 34% to $10.1 million; revenue drops 5% to $22.8 million
L
LUNG• Full-year outlook maintained
- Full-year revenue outlook maintained at USD 90 million to USD 92 million; gross margin view raised to about 76%.
Pulmonx reports lower revenue and narrower loss in Q2 FY26
- Pulmonx Q2 2026 revenue fell 5% from a year earlier to USD 22.8 million, with U.S. revenue down 4% to USD 14.2 million.
- International revenue dropped 6% to USD 8.6 million, attributed to no sales into China while awaiting renewal of a registration certificate.
- GAAP net loss narrowed to USD 10.1 million, or USD 0.24 per share, from USD 15.2 million, or USD 0.38 per share.
- Gross margin expanded 6 percentage points to a record 78%, while operating expenses decreased 16% to USD 26.8 million.
